Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing and fewer safety risks.

Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center has found an efficacy signal for a CD19-targeted CAR NK cell therapy that is in line with marketed CAR T cells against the same target...